Regeneron Pharmaceuticals Receives Neutral Rating from Zacks (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “neutral” rating reaffirmed by Zacks in a research note issued to investors on Friday, Stock Ratings Network.com reports. They currently have a $344.00 price target on the stock. Zacks‘ price target indicates a potential upside of 5.00% from the company’s current price.
Zacks‘ analyst wrote, “Regeneron’s fourth quarter 2013 adjusted earnings of $1.75 per share surpassed the Zacks Consensus Estimate of $1.01. Revenues soared 47% to $610 million, well above the Zacks Consensus Estimate of $580 million. Strong sales of Eylea boosted results in the quarter. Encouraged by the strong sales of the eye drug, Regeneron provided an encouraging forecast for 2014 on Eylea. Regeneron expects 2014 sales of the eye drug in the range of $1.7-$1.8 billion, well above 2013 levels Eylea is expected to continue performing well, thereby driving growth at Regeneron. We expect investor focus to remain on label expansion efforts for Eylea and maintain our Neutral recommendation on the stock.”
In other Regeneron Pharmaceuticals news, VP Michael Aberman sold 3,648 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $331.42, for a total value of $1,209,020.16. Following the completion of the transaction, the vice president now directly owns 15,600 shares of the company’s stock, valued at approximately $5,170,152. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 3.25% during mid-day trading on Friday, hitting $338.26. The stock had a trading volume of 1,010,088 shares. Regeneron Pharmaceuticals has a one year low of $157.65 and a one year high of $334.83. The stock has a 50-day moving average of $291.4 and a 200-day moving average of $282.1. The company has a market cap of $33.441 billion and a price-to-earnings ratio of 85.99.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 11th. The company reported $2.24 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.97 by $1.27. The company had revenue of $610.00 million for the quarter, compared to the consensus estimate of $579.17 million. During the same quarter in the prior year, the company posted $1.47 earnings per share. The company’s quarterly revenue was up 47.0% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $4.55 earnings per share for the current fiscal year.
REGN has been the subject of a number of other recent research reports. Analysts at Oppenheimer downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 13th. They now have a $325.00 price target on the stock, up previously from $310.00. They noted that the move was a valuation call. Separately, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $344.00 to $348.00 in a research note on Thursday, February 13th. Finally, analysts at Goldman Sachs raised their price target on shares of Regeneron Pharmaceuticals from $353.00 to $383.00 in a research note on Thursday, February 13th. They now have a “market perform” rating on the stock. Seven research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Regeneron Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $317.91.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.